Find a Clinical Trial

Find a Clinical Trial

Search by practice name, trial titles, indicators and specific disease types.

Lymphomas

Clinical Trial at: Texas Oncology - Wichita Falls

(SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

  • Details

ClinicalTrials.gov ID: NCT01716806
Diagnosis Type: Hodgkins
USOR Number: 11282

  • Practice Details

5400 Kell West Blvd
Wichita Falls, Texas 76310
274.39 mi. away
P: (940) 691-8271

More Details View Practice Page

Prostate Cancer

Clinical Trial at: Texas Oncology - Wichita Falls

TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency (CO-338-063)

  • Details

ClinicalTrials.gov ID: NCT02975934
Diagnosis Type: NA
USOR Number: 16238

  • Practice Details

5400 Kell West Blvd
Wichita Falls, Texas 76310
274.39 mi. away
P: (940) 691-8271

More Details View Practice Page

Urothelial Cancer

Clinical Trial at: Texas Oncology - Allen

A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

  • Details

ClinicalTrials.gov ID: NCT03288545
Diagnosis Type: NA
USOR Number: 20172

  • Practice Details

1105 Central Expressway, Suite 320
Allen, Texas 75013
279.71 mi. away
P: (469) 467-4392

More Details View Practice Page

Bladder Cancer

Clinical Trial at: Texas Oncology - Allen

A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

  • Details

ClinicalTrials.gov ID: NCT03288545
Diagnosis Type: NA
USOR Number: 20172

  • Practice Details

1105 Central Expressway, Suite 320
Allen, Texas 75013
279.71 mi. away
P: (469) 467-4392

More Details View Practice Page

Urothelial Cancer

Clinical Trial at: Texas Oncology - Allen

A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

  • Details

ClinicalTrials.gov ID: NCT03288545
Diagnosis Type: NA
USOR Number: 20172

  • Practice Details

1105 Central Expressway, Suite 320
Allen, Texas 75013
279.71 mi. away
P: (469) 467-4392

More Details View Practice Page

Bladder Cancer

Clinical Trial at: Texas Oncology - Allen

A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

  • Details

ClinicalTrials.gov ID: NCT03288545
Diagnosis Type: NA
USOR Number: 20172

  • Practice Details

1105 Central Expressway, Suite 320
Allen, Texas 75013
279.71 mi. away
P: (469) 467-4392

More Details View Practice Page

Prostate Cancer

Clinical Trial at: Texas Oncology - Allen

A Phase 1b-2 Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer (PCR2002 Quest) (64091742PCR2002)

  • Details

ClinicalTrials.gov ID: NCT03431350
Diagnosis Type: NA
USOR Number: 19146

  • Practice Details

1105 Central Expressway, Suite 320
Allen, Texas 75013
279.71 mi. away
P: (469) 467-4392

More Details View Practice Page

Prostate Cancer

Clinical Trial at: Texas Oncology - Allen

A Phase 1b-2 Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer (PCR2002 Quest) (64091742PCR2002)

  • Details

ClinicalTrials.gov ID: NCT03431350
Diagnosis Type: NA
USOR Number: 19146

  • Practice Details

1105 Central Expressway, Suite 320
Allen, Texas 75013
279.71 mi. away
P: (469) 467-4392

More Details View Practice Page

Leukemia

Clinical Trial at: Texas Oncology - Allen

ULTRA-V: Phase 2 Study to Assess the Efficacy and Safety of Ublituximab in Combination with Umbralisib and Venetoclax (U2-V) in Subjects with Chronic Lymphocytic Leukemia (CLL)(U2-VEN-207)

  • Details

ClinicalTrials.gov ID: NCT03801525
Diagnosis Type: CLL
USOR Number: 19205

  • Practice Details

1105 Central Expressway, Suite 320
Allen, Texas 75013
279.71 mi. away
P: (469) 467-4392

More Details View Practice Page

Prostate Cancer

Clinical Trial at: Texas Oncology - Allen

A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

  • Details

ClinicalTrials.gov ID: NCT03706365
Diagnosis Type: NA
USOR Number: 18128

  • Practice Details

1105 Central Expressway, Suite 320
Allen, Texas 75013
279.71 mi. away
P: (469) 467-4392

More Details View Practice Page

Prostate Cancer

Clinical Trial at: Texas Oncology - Allen

A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

  • Details

ClinicalTrials.gov ID: NCT03706365
Diagnosis Type: NA
USOR Number: 18128

  • Practice Details

1105 Central Expressway, Suite 320
Allen, Texas 75013
279.71 mi. away
P: (469) 467-4392

More Details View Practice Page

Prostate Cancer

Clinical Trial at: Texas Oncology - Allen

A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer(64091742PCR3001)

  • Details

ClinicalTrials.gov ID: NCT03748641
Diagnosis Type: NA
USOR Number: 18103

  • Practice Details

1105 Central Expressway, Suite 320
Allen, Texas 75013
279.71 mi. away
P: (469) 467-4392

More Details View Practice Page

Prostate Cancer

Clinical Trial at: Texas Oncology - Allen

A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer(64091742PCR3001)

  • Details

ClinicalTrials.gov ID: NCT03748641
Diagnosis Type: NA
USOR Number: 18103

  • Practice Details

1105 Central Expressway, Suite 320
Allen, Texas 75013
279.71 mi. away
P: (469) 467-4392

More Details View Practice Page

Gall Bladder Cancer

Clinical Trial at: Texas Oncology - Allen

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

  • Details

ClinicalTrials.gov ID: NCT03773302
Diagnosis Type: NA
USOR Number: 18264

  • Practice Details

1105 Central Expressway, Suite 320
Allen, Texas 75013
279.71 mi. away
P: (469) 467-4392

More Details View Practice Page

Gall Bladder Cancer

Clinical Trial at: Texas Oncology - Allen

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

  • Details

ClinicalTrials.gov ID: NCT03773302
Diagnosis Type: NA
USOR Number: 18264

  • Practice Details

1105 Central Expressway, Suite 320
Allen, Texas 75013
279.71 mi. away
P: (469) 467-4392

More Details View Practice Page

Lymphomas

Clinical Trial at: Texas Oncology - Allen

(SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

  • Details

ClinicalTrials.gov ID: NCT01716806
Diagnosis Type: Non-Hodgkins
USOR Number: 11282

  • Practice Details

1105 Central Expressway, Suite 320
Allen, Texas 75013
279.71 mi. away
P: (469) 467-4392

More Details View Practice Page

Lymphomas

Clinical Trial at: Texas Oncology - Allen

(SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

  • Details

ClinicalTrials.gov ID: NCT01716806
Diagnosis Type: Non-Hodgkins
USOR Number: 11282

  • Practice Details

1105 Central Expressway, Suite 320
Allen, Texas 75013
279.71 mi. away
P: (469) 467-4392

More Details View Practice Page

Lung Cancer

Clinical Trial at: Texas Oncology - Allen

A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer (BLU-667-2303)

  • Details

ClinicalTrials.gov ID: NCT04222972
Diagnosis Type: NA
USOR Number: 19208

  • Practice Details

1105 Central Expressway, Suite 320
Allen, Texas 75013
279.71 mi. away
P: (469) 467-4392

More Details View Practice Page

Lung Cancer

Clinical Trial at: Texas Oncology - Allen

A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer (BLU-667-2303)

  • Details

ClinicalTrials.gov ID: NCT04222972
Diagnosis Type: NA
USOR Number: 19208

  • Practice Details

1105 Central Expressway, Suite 320
Allen, Texas 75013
279.71 mi. away
P: (469) 467-4392

More Details View Practice Page

Essential Thrombocythemia

Clinical Trial at: Texas Oncology - Allen

A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203)

  • Details

ClinicalTrials.gov ID: NCT03165734
Diagnosis Type: NA
USOR Number: 19171

  • Practice Details

1105 Central Expressway, Suite 320
Allen, Texas 75013
279.71 mi. away
P: (469) 467-4392

More Details View Practice Page

Pages